Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NC 410

Next Previous
Drug Profile

NC 410

Alternative Names: NC-410

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University School of Medicine
  • Developer Merck Sharp & Dohme; NextCure
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Dendritic cell stimulants; Leukocyte-associated immunoglobulin-like receptor 1 antagonists; Myeloid cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 16 Apr 2025 NextCure plans a phase II trial for Pancreatic Cancer (Metastatic disease, First-line therapy, Combination therapy) in USA (NCT06941857) in June 2025
  • 16 Sep 2024 Efficacy data from a phase Ib/II trial in Ovarian and Colorectal cancer released by Nextcure
  • 13 Sep 2024 Efficacy and adverse events data from the phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top